title: [Prevention Effect of Thymosin-alpha1 Aganist Early Ventilator-associated Pneumonia in Patients with Mechanical Ventilation].
abstract: OBJECTIVE
  To investigate the preventive effects of thymosin-alpha1 against early ventilator-associated pneumonia (VAP) in the patients with mechanical ventilation.
  
  
  METHODS
  Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random. The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d). The incidence and occurrence time of VAP were observed, and the time of mechanical ventilation and ICU stay were recorded. The levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte, CD14+ mononuclear cell human leukocyte antigens-DR (CD14+ HLA-DR) and procalcitonin (PCT) were detected before mechanical ventilation and at the 3d and 7th d after mechanical ventilation.
  
  
  RESULTS
  The base line including the level of immunologic function had no difference between the two groups (P>0.05). The incidence of VAP in thymosin therapy group was lower than that in routine therapy group, but it was not significant difference (P>0.05). The durations of machine ventilation and ICU stay in thymosin therapy group were shorter than those in routine therapy group (P<0.05). The occurrence time of VAP in thymosin therapy group was significantly later than that in routine therapy group (P<0.05). At the 3rd and 7th d after mechanical ventilation, thymosin therapy group achived higher levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte and CD14+ HLA-DR than routine therapy group did (P<0.05).
  
  
  CONCLUSIONS
  Thymosinal may be able to improve immunologic function and prevent the incidence of early VAP in the patients with mechanical ventilation.
authors: Song-song
authors: SS
authors: Zhang
authors: Kun
authors: K
authors: Li
authors: Yu-hui
authors: YH
authors: Wang
authors: Ba-ning
authors: BN
authors: Ye
authors: Yu
authors: Y
authors: Pan
authors: Xian-qing
authors: XQ
authors: Shi
mesh_terms: D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000276:immunology; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D007362:Intensive Care Units; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D053717:Pneumonia, Ventilator-Associated / Q000517:prevention & control*; D011498:Protein Precursors / Q000097:blood; D012121:Respiration, Artificial; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C468811:C-9,11,21-trisnor-17-methyl-1, 25-dihydroxyvitamin D3; C000606589:CALCA protein, human; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors; D011498:Protein Precursors; D002762:Cholecalciferol; D013947:Thymosin; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide; D000077596:Thymalfasin